HER2 receptor

Dimerized HER2 receptors signal tumor cells to proliferate... 

Herceptin HER2 receptor monoclonal antibody, recombinant... 

Rauser S, Marquardt C, Balluff B, Deininger S, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert M, Schmitt M, Aubele M, Hofler H, Walch A (2010) Classification of HER2 receptor status in breast cancer tissue by MALDI imaging mass spectrometry. J Proteome Res 9 1854-1863. doi 10.1021/pr901008d... 

Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749. 

An interaction of doxorubicin with the anti-HER2 receptor humanized monoclonal antibody, trastuzumab (Herceptin), has been reported. Most patients who received trastuzumab in early trials had been pretreated with anthracyclines. Despite this, preliminary information suggested that reduced systolic cardiac function was an adverse effect of trastuzumab (119). More recently, this problem has been further highlighted in a study of women with metastatic breast cancer (120). Patients who had not received prior anthracycline-containing adjuvant chemotherapy were at greater risk of cardiotoxicity when they received trastuzumab in combination with doxorubicin or cyclophosphamide (27 and 75% respectively), compared with only 11% of patients who received trastuzumab in combination with pachtaxel (120,121). The risk of cardiac events in patients treated with doxorubicin, cyclophosphamide, and trastuzumab increased markedly after a cumulative doxorubicin dose of 360 mg/m. This suggests synergistic cardiotoxicity with trastuzumab and doxorubicin. Trastuzumab is therefore currently licensed only for use in conjunction with pacli-taxel or docetaxel and not with conventional doxorubicin. 

HER2 receptor, which when overexpressed, is associated with breast cancer and stomach cancer Abbreviations CLIO, cross-linked iron oxide CNTs, carbon nanotuhes. 

MoAB directed against HER2 receptors, overexpressed in some breast cancer patients and related to epidermal growth factor... 

Fig. 5.2 The HER family of tyrosine kinase receptors. Known ligands for each receptor are indicated. No ligand is identified for the HER2 receptor. The HER3 receptor lacks adequate intrinsic tyrosine kinase activity.

Accelerating the internalization and degradation of HER2 receptors from the cell membrane [32-36]. 

In some cases, a point mutation changes a normal RTK Into one that dimerizes and is constitutively active in the absence of ligand. For instance, a single point mutation converts the normal Her2 receptor into the Neu oncoprotein, which Is an Initiator of certain mouse cancers (Figure 23-14, lefi). Similarly, human tumors called multiple endocrine neoplasia type 2 produce a constitutively active dimeric Glia-derived neurotrophic factor (GDNF) receptor that results... 

Mitri, Z., Constantine, T., O Regan, R. The HER2 Receptor in Breast Cancer Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother. Res. Pract. 743193 (2012). PMCID 3539433... 

Veijat, T. Detection of gene expression of estrogen receptor, progesterone receptor or HER2 receptor for diagnosis of human breast cancer. Fr. Demande FR 2863275, 2005 Chem. Abstr. 2005, 143, 39108. 

---